Quanterix Co. (NASDAQ:QTRX) Shares Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC boosted its position in Quanterix Co. (NASDAQ:QTRX) by 34.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,738 shares of the company’s stock after purchasing an additional 3,279 shares during the period. Hsbc Holdings PLC’s holdings in Quanterix were worth $164,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Lord Abbett & CO. LLC grew its holdings in Quanterix by 22.9% during the first quarter. Lord Abbett & CO. LLC now owns 1,757,153 shares of the company’s stock worth $41,398,000 after acquiring an additional 326,876 shares during the period. Superstring Capital Management LP acquired a new stake in Quanterix during the fourth quarter valued at approximately $1,962,000. Williams Jones Wealth Management LLC. bought a new stake in Quanterix during the first quarter worth approximately $1,327,000. Easterly Investment Partners LLC increased its holdings in shares of Quanterix by 551.1% in the first quarter. Easterly Investment Partners LLC now owns 78,734 shares of the company’s stock valued at $1,855,000 after buying an additional 66,642 shares in the last quarter. Finally, Harbor Capital Advisors Inc. lifted its position in shares of Quanterix by 772.3% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 83,941 shares of the company’s stock valued at $1,109,000 after acquiring an additional 74,318 shares during the last quarter. 86.48% of the stock is currently owned by institutional investors and hedge funds.

Quanterix Trading Up 0.1 %

Shares of NASDAQ QTRX opened at $11.90 on Friday. The firm has a market capitalization of $455.41 million, a PE ratio of -12.40 and a beta of 1.36. Quanterix Co. has a one year low of $10.50 and a one year high of $29.70. The business has a 50-day moving average price of $12.94 and a two-hundred day moving average price of $15.38.

Quanterix (NASDAQ:QTRX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). Quanterix had a negative net margin of 30.71% and a negative return on equity of 11.52%. The company had revenue of $34.38 million for the quarter, compared to analysts’ expectations of $34.19 million. During the same period in the previous year, the firm posted ($0.16) earnings per share. Research analysts anticipate that Quanterix Co. will post -0.88 EPS for the current year.

Insider Transactions at Quanterix

In other news, Director David R. Walt bought 47,000 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were bought at an average cost of $13.29 per share, with a total value of $624,630.00. Following the transaction, the director now directly owns 1,487,342 shares in the company, valued at approximately $19,766,775.18. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 6.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Scotiabank decreased their target price on Quanterix from $32.00 to $28.00 and set a “sector outperform” rating on the stock in a report on Monday, August 12th. TD Cowen reduced their price objective on shares of Quanterix from $17.00 to $15.00 and set a “hold” rating for the company in a research note on Friday, August 9th. Finally, The Goldman Sachs Group dropped their target price on shares of Quanterix from $35.00 to $24.00 and set a “buy” rating on the stock in a research report on Tuesday, July 9th.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.